ramucirumab,pembrolizumab
eli lilly,merck
['lcsm,(-blcsm)', 'sclc', 'nsclc', 'ramucirumab', 'pembrolizumab']
new research from , &amp; colleagues shows combo of ramucirumab &amp; pembrolizumab reduced risk of death by 31% in patients with advanced #nsclc that had progressed on prior immunotherapy. #asco22 #lcsm 
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.